Field Effectiveness of Bacillus thuringiensis israelensis (Bti) against Aedes (Stegomyia) aegypti (Linnaeus) in Ornamental Ceramic Containers with Common Aquatic Plants

This study was undertaken to determine the impact of larvaciding using a Bti (Bacillus thuringiensis israelensis) formulation (VectoBac WG) against Aedes aegypti larvae in earthen jars containing aquatic plants. Aquatic plants commonly used for landscaping, Pistia stratiotes (L.) (Liliopsida: Araceae) and Sagittaria sp. (Liliopsida: Alismataceae) were placed inside earthen jars filled with 50 L tap water. All earthen jars were treated with Bti formulation at 8g/1000L. Untreated jars with and without aquatic plants were also set up as controls. Fifty laboratory-bred 2nd instar larvae were introduced into each earthen jar. All earthen jars were observed daily. Number of adults emerged was recorded and the larval mortality was calculated. The indicators of effectiveness of Bti for these studies were (i) residual activities of Bti, and (ii) larval mortality in earthen jars with or without aquatic plants. The treated earthen jars containing P. stratiotes and Sagittaria sp. showed significant residual larvicidal effect up to 7 weeks, in comparison to untreated control (p < 0.05). The larval mortality ranged from 77.34-100 for jars with aquatic plants vs 80.66-100 for jars without aquatic plant. Earthen jars treated with Bti without aquatic plants also exhibited significantly longer residual larvicidal activity of up to 10 weeks (p < 0.05). The larval mortality ranged from 12.66-100 for jars with aquatic plants vs 59.34 — 100 for jars without aquatic plant. Thus, earthen jars without aquatic plants exhibited longer residual larvicidal effect compared to those with aquatic plants. This study suggested that containers with aquatic plants for landscaping should be treated more frequently with Bti in view of the shortened residual activity

Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).

In the phase 3 POSEIDON study, first-line tremelimumab plus durvalumab and chemotherapy significantly improved overall survival and progression-free survival versus chemotherapy in metastatic non-small-cell lung cancer (NSCLC). We present patient-reported outcomes (PROs). Treatment-naïve patients were randomized 1:1:1 to tremelimumab plus durvalumab and chemotherapy, durvalumab plus chemotherapy, or chemotherapy. PROs (prespecified secondary endpoints) were assessed using the European Organisation for Research and Treatment of Cancer 30-item core quality of life questionnaire version 3 (QLQ-C30) and its 13-item lung cancer module (QLQ-LC13). We analyzed time to deterioration (TTD) of symptoms, functioning, and global health status/quality of life (QoL) from randomization by log-rank test and improvement rates by logistic regression. 972/1013 (96 %) patients randomized completed baseline QLQ-C30 and QLQ-LC13 questionnaires, with scores comparable between treatment arms. Patients receiving tremelimumab plus durvalumab and chemotherapy versus chemotherapy had longer median TTD for all PRO items. Hazard ratios for TTD favored tremelimumab plus durvalumab and chemotherapy for all items except diarrhea; 95 % confidence intervals did not cross 1.0 for global health status/QoL, physical functioning, cognitive functioning, pain, nausea/vomiting, insomnia, constipation, hemoptysis, dyspnea, and pain in other parts. For durvalumab plus chemotherapy, median TTD was longer versus chemotherapy for all items except nausea/vomiting and diarrhea. Hazard ratios favored durvalumab plus chemotherapy for all items except appetite loss; 95 % confidence intervals did not cross 1.0 for global health status/QoL, physical functioning, role functioning, dyspnea, and pain in other parts. For both immunotherapy plus chemotherapy arms, improvement rates in all PRO items were numerically higher versus chemotherapy, with odds ratios &gt; 1. Tremelimumab plus durvalumab and chemotherapy delayed deterioration in symptoms, functioning, and global health status/QoL compared with chemotherapy. Together with significant improvements in survival, these results support tremelimumab plus durvalumab and chemotherapy as a first-line treatment option in metastatic NSCLC

Scaling limit of virtual states of triatomic systems

For a system with three identical atoms, the dependence of the $s-$wave virtual state energy on the weakly bound dimer and trimer binding energies is calculated in a form of a universal scaling function. The scaling function is obtained from a renormalizable three-body model with a pairwise Dirac-delta interaction. It was also discussed the threshold condition for the appearance of the trimer virtual state.Comment: 9 pages, 3 figure

The ^4He trimer as an Efimov system

We review the results obtained in the last four decades which demonstrate the Efimov nature of the $^4$He three-atomic system.Comment: Review article for a special issue of the Few-Body Systems journal devoted to Efimov physic

Spectroscopic factor and proton formation probability for the d3/2 proton emitter 151mLu

The quenching of the experimental spectroscopic factor for proton emission from the short-lived d3/2 isomeric state in 151mLu was a long-standing problem. In the present work, proton emission from this isomer has been reinvestigated in an experiment at the Accelerator Laboratory of the University of Jyväskylä. The proton-decay energy and half-life of this isomer were measured to be 1295(5) keV and 15.4(8) μs, respectively, in agreement with another recent study. These new experimental data can resolve the discrepancy in the spectroscopic factor calculated using the spherical WKB approximation. Using the R-matrix approach it is found that the proton formation probability indicates no significant hindrance for the proton decay of 151mLu